URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

David Watson Biography and Net Worth

General Counsel of Apellis Pharmaceuticals

Mr. Watson has been general counsel of Apellis Pharmaceuticals since 2014. Previously, Mr. Watson was a member at Frost Brown Todd LLC, where his practice included equity finance, mergers & acquisitions, and securities transactions. Mr. Watson is a graduate of Harvard College (BA, magna cum laude, Phi Beta Kappa), Vanderbilt Law School (JD) and the University of Kentucky (MA, mathematics).

What is David O. Watson's net worth?: The estimated net worth of David O. Watson is at least $3.43 million as of February 12th, 2024. Mr. Watson owns 103,390 shares of Apellis Pharmaceuticals stock worth more than $3,433,582 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Watson may own. Additionally, Mr. Watson receives a salary of $764,370.00 as General Counsel at Apellis Pharmaceuticals. Learn More about David O. Watson's net worth.
How old is David O. Watson?: Mr. Watson is currently 51 years old. There are 6 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corporate Controller & Chief Accounting Officer, who is 57 years old. Learn More on David O. Watson's age.
What is David O. Watson's salary?: As the General Counsel of Apellis Pharmaceuticals, Inc., Mr. Watson earns $764,370.00 per year. There are 4 executives that earn more than Mr. Watson. The highest earning executive at Apellis Pharmaceuticals is Dr. Cedric Francois M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,440,000.00 per year. Learn More on David O. Watson's salary.
How do I contact David O. Watson?: The corporate mailing address for Mr. Watson and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on David O. Watson's contact information.
Has David O. Watson been buying or selling shares of Apellis Pharmaceuticals?: David O. Watson has not been actively trading shares of Apellis Pharmaceuticals during the last quarter. Most recently, David O. Watson sold 781 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a transaction totalling $52,928.37. Following the completion of the sale, the general counsel now directly owns 103,390 shares of the company's stock, valued at $7,006,740.30. Learn More on David O. Watson's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 30 times. They sold a total of 578,005 shares worth more than $32,477,597.17. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 9/16/2024.

David O. Watson Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/12/2024	Sell	781	$67.77	$52,928.37	103,390
1/29/2024	Sell	906	$64.14	$58,110.84	104,171
1/22/2024	Sell	4,184	$65.00	$271,960.00	105,077
1/16/2024	Sell	4,240	$66.81	$283,274.40	109,261
12/19/2023	Sell	3,905	$57.23	$223,483.15	89,753
7/3/2023	Sell	8,510	$89.98	$765,729.80	85,753
6/22/2022	Sell	10,000	$44.51	$445,100.00	115,569
4/25/2022	Sell	5,000	$50.00	$250,000.00	125,569
12/27/2021	Sell	1,200	$48.50	$58,200.00
12/22/2021	Sell	10,571	$47.81	$505,399.51
12/14/2020	Sell	18,333	$50.94	$933,883.02
9/14/2018	Sell	15,776	$18.78	$296,273.28

David O. Watson Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $33.21

$32.89

$34.27

50 Day Range

MA: $30.31

$26.18

$35.42

2 Week Range

Now: $33.21

$24.34

$73.80

Volume

3,733,222 shs

Average Volume

2,007,418 shs

Market Capitalization

$4.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

David Watson Biography and Net Worth

What is David O. Watson's net worth?

How old is David O. Watson?

What is David O. Watson's salary?

How do I contact David O. Watson?

Has David O. Watson been buying or selling shares of Apellis Pharmaceuticals?

Who are Apellis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Apellis Pharmaceuticals?